Skip to Content

Eptifibatide Pregnancy and Breastfeeding Warnings

Eptifibatide is also known as: Integrilin

Medically reviewed on August 27, 2018

Eptifibatide Pregnancy Warnings

Eptifibatide has been assigned to pregnancy category B by the FDA. Animal data have failed to reveal evidence of fetotoxicity after administration of doses equivalent to 4 times the maximum recommended human daily dose. There are no adequate or controlled data from human pregnancy studies. Eptifibatide should only be used during pregnancy when need has been clearly established.

See references

Eptifibatide Breastfeeding Warnings

There are no data on the excretion of eptifibatide in human milk. Because many drugs are excreted in human milk, caution should be exercised when eptifibatide is administered to a nursing mother.

See references

References for pregnancy information

  1. "Product Information. Integrilin (eptifibatide)." Schering Laboratories, Kenilworth, NJ.

References for breastfeeding information

  1. "Product Information. Integrilin (eptifibatide)." Schering Laboratories, Kenilworth, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide